玻璃体内抗 VEGF 药物是否有全身作用的证据，我们是否应该关注？
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
出版信息
Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i7-10. doi: 10.1136/bjophthalmol-2013-303844. Epub 2013 Dec 10.
Abstract
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.
摘要
抗血管内皮生长因子 (VEGF) 治疗已经彻底改变了视网膜疾病的治疗方法，而且似乎非常安全。然而，有几条证据线表明，这些药物的小剂量可能具有潜在的全身作用。这些全身作用的临床意义尚不清楚，但需要进一步研究。
相似文献
1
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?玻璃体内抗 VEGF 药物是否有全身作用的证据，我们是否应该关注？
Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i7-10. doi: 10.1136/bjophthalmol-2013-303844. Epub 2013 Dec 10.
2
Introduction. Treatment paradigms within the use of anti-VEGF agents.引言。抗血管内皮生长因子（VEGF）药物使用中的治疗模式。
Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i1-2. doi: 10.1136/bjophthalmol-2014-305502.
3
Expounding newer vistas in VEGF.阐述血管内皮生长因子的新视野。
Indian J Ophthalmol. 2013 Jan-Feb;61(1):1-2. doi: 10.4103/0301-4738.105047.
4
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.抗血管内皮生长因子药物玻璃体内注射相关的不良反应和并发症：文献复习。
Eye (Lond). 2013 Jul;27(7):787-94. doi: 10.1038/eye.2013.107. Epub 2013 May 31.
5
Intravitreal anti-VEGF therapy for retinal macroaneurysm.玻璃体内抗血管内皮生长因子疗法治疗视网膜大动脉瘤
Klin Monbl Augenheilkd. 2013 Apr;230(4):392-5. doi: 10.1055/s-0032-1328377. Epub 2013 Apr 29.
6
Whither (or Wither) Adherence to Retina Trial Protocols in Clinical Practice?临床实践中对视网膜试验方案的坚持何去何从？
Ophthalmic Surg Lasers Imaging Retina. 2017 Sep 1;48(9):692-698. doi: 10.3928/23258160-20170829-02.
7
Changing paradigms of anti-VEGF in the Indian scenario.改变印度抗 VEGF 治疗模式。
Indian J Ophthalmol. 2014 Jan;62(1):88-92. doi: 10.4103/0301-4738.126189.
8
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.同一天行双侧玻璃体内抗血管内皮生长因子注射：加拿大一大型视网膜中心的经验。
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
9
Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor.玻璃体内注射抗血管内皮生长因子时疼痛的相关因素。
Eye (Lond). 2018 Sep;32(9):1544-1546. doi: 10.1038/s41433-018-0126-z. Epub 2018 May 17.
10
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.用于治疗早产儿视网膜病变的抗血管内皮生长因子（VEGF）药物。
Cochrane Database Syst Rev. 2016;2:CD009734. doi: 10.1002/14651858.CD009734.pub2. Epub 2016 Feb 27.
引用本文的文献
1
Ophthalmic conditions affecting the choroid and retina in pregnancy: An overview of key pathologies.孕期影响脉络膜和视网膜的眼科疾病：关键病理学概述
Obstet Med. 2025 Sep 10:1753495X251367092. doi: 10.1177/1753495X251367092.
2
Collaborative care for pregnant women with eye conditions.患有眼部疾病孕妇的协作式护理。
Clin Med (Lond). 2025 Apr 5;25(3):100314. doi: 10.1016/j.clinme.2025.100314.
3
CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study.创新型雷珠单抗与生物类似药雷珠单抗在脉络膜视网膜血管疾病中的比较安全性分析——CRsIBS研究
Clin Ophthalmol. 2025 Mar 28;19:1093-1102. doi: 10.2147/OPTH.S515479. eCollection 2025.
4
Intravitreal therapy-success stories and challenges.玻璃体内注射疗法——成功案例与挑战
Wien Med Wochenschr. 2025 May;175(7-8):162-174. doi: 10.1007/s10354-024-01070-8. Epub 2025 Mar 3.
5
Cardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications.癌症患者的心血管疾病：流行病学趋势、心脏并发症及预后影响的综合综述
Chin Med J (Engl). 2025 Jan 20;138(2):143-154. doi: 10.1097/CM9.0000000000003419. Epub 2024 Dec 23.
6
Epithelial Membrane Protein 2 (EMP2) Blockade Attenuates Pathological Neovascularization in Murine Oxygen-Induced Retinopathy.上皮膜蛋白 2（EMP2）阻断减轻小鼠氧诱导性视网膜病变中的病理性血管生成。
Invest Ophthalmol Vis Sci. 2024 Jul 1;65(8):10. doi: 10.1167/iovs.65.8.10.
7
Next generation therapeutics for retinal neurodegenerative diseases.视网膜神经退行性疾病的下一代治疗方法。
J Control Release. 2024 Mar;367:708-736. doi: 10.1016/j.jconrel.2024.01.063. Epub 2024 Feb 10.
8
End binding-3 inhibitor activates regenerative program in age-related macular degeneration.末端结合-3 抑制剂激活与年龄相关的黄斑变性的再生程序。
Cell Rep Med. 2023 Oct 17;4(10):101223. doi: 10.1016/j.xcrm.2023.101223. Epub 2023 Oct 3.
9
Blockade of Annexin A2 Prevents Early Microvasculopathy in Murine Models of Diabetic Retinopathy.阻断 annexin A2 可预防糖尿病视网膜病变小鼠模型的早期微血管病变。
Invest Ophthalmol Vis Sci. 2023 Apr 3;64(4):33. doi: 10.1167/iovs.64.4.33.
10
Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network.使用生成对抗网络预测新生血管性年龄相关性黄斑变性对抗血管内皮生长因子药物的特异性治疗效果。
Sci Rep. 2023 Apr 6;13(1):5639. doi: 10.1038/s41598-023-32398-7.
本文引用的文献
1
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.抑制年龄相关性脉络膜新生血管中 VEGF 的替代治疗：IVAN 随机对照试验的 2 年发现。
Lancet. 2013 Oct 12;382(9900):1258-67. doi: 10.1016/S0140-6736(13)61501-9. Epub 2013 Jul 19.
2
Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye.比较单侧玻璃体内注射贝伐单抗和雷珠单抗对糖尿病患者对侧眼黄斑水肿的疗效。
J Ocul Pharmacol Ther. 2013 Oct;29(8):728-32. doi: 10.1089/jop.2013.0049. Epub 2013 Jul 13.
3
Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.单侧注射贝伐单抗治疗早产儿视网膜病变的双侧效应
JAMA Ophthalmol. 2013 Aug;131(8):1099-101. doi: 10.1001/jamaophthalmol.2013.400.
4
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.雷珠单抗治疗糖尿病黄斑水肿的长期疗效：两项 III 期临床试验（RISE 和 RIDE）的 36 个月结果。
Ophthalmology. 2013 Oct;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034. Epub 2013 May 22.
5
Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.年龄相关性黄斑变性治疗试验中对侧眼脉络膜新生血管的发生率比较。
Ophthalmology. 2013 Oct;120(10):2035-41. doi: 10.1016/j.ophtha.2013.03.017. Epub 2013 May 22.
6
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.血管内皮生长因子在年龄相关性黄斑变性和糖尿病性黄斑水肿患者玻璃体内注射贝伐单抗、雷珠单抗和聚乙二醇化阿柏西普前后的血浆水平。
Br J Ophthalmol. 2013 Apr;97(4):454-9. doi: 10.1136/bjophthalmol-2012-302451. Epub 2013 Feb 5.
7
Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials.随机对照试验中接受雷珠单抗治疗脉络膜新生血管的患者的脑血管意外。
Retina. 2012 Oct;32(9):1821-8. doi: 10.1097/IAE.0b013e31825db6ba.
8
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.贝伐单抗和雷珠单抗的安全性回顾和荟萃分析：超适应证与金标准。
PLoS One. 2012;7(8):e42701. doi: 10.1371/journal.pone.0042701. Epub 2012 Aug 3.
9
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.雷珠单抗与贝伐单抗治疗新生血管性年龄相关性黄斑变性：IVAN 随机试验一年期结果。
Ophthalmology. 2012 Jul;119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015. Epub 2012 May 11.
10
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性：两年结果。
Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.
Zotero 插件